13F Insight
DOSSIER · 13F-HR · Q2 2026

Frazier Life Sciences Management, L.P.

$4.6B in tracked AUM across 41 positions as of Q2 2026.

FL
CIK 0001892134 · last filed Jun 30, 2026
Total AUM
$4.6B
as of Q2 2026
Holdings
41
—
positions
Whale Score
72
72
strong
Activity
—
no data
changes this Q
AI Analysis · Q2 2026

Portfolio Overview

Frazier Life Sciences Management, L.P. manages a highly concentrated, specialized portfolio totaling approximately $1.93 billion across 33 holdings as of the report date September 30, 2025. The firm employs a high-conviction investment strategy, evidenced by the portfolio's narrow focus and significant allocation to single names. The portfolio experienced a substantial decrease in value of 22.9% (dropping from $2.50B in the previous quarter), a decline driven by a combina...

Key Holdings

The portfolio is dominated by NewAmsterdam Pharma Company, which stands as the singular largest holding with a value of $475 million, representing a massive 24.62% portfolio allocation. This indicates an exceptionally high level of conviction in this specific name. The next tier of significant holdings includes BridgeBio Pharma Inc (BBIO) at 10.35% ($199.73M) and Arcutis Biotherapeutics Inc (ARQT) at 9.65% ($186.13M). Together, these top three names signal a heavy tilt toward clinical-stage and commercial-stage biotechnology companies focusing on specific therapeutic areas such as cardiometabolic and dermatological diseases.

Analysis generated by 13F Insight from SEC Form 13F filing data · Q2 2026. Methodology

Quarter at a glance — Q2 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q2 2026.

#HoldingValueSharesWeight
01
MIRM
MIRUM PHARMACEUTICALS INC
$899M7.7M19.6%02
N62509109
NEWAMSTERDAM PHARMA COMPANY
$613M18.1M13.3%03
ERAS
ERASCA INC
$458M25.0M10.0%04
MBX
MBX BIOSCIENCES INC
$367M6.7M8.0%05
ARQT
ARCUTIS BIOTHERAPEUTICS INC
$259M9.9M5.6%06
TRVI
TREVI THERAPEUTICS INC
$185M9.9M4.0%07
KRYS
KRYSTAL BIOTECH INC
$179M481K3.9%08
MAZE
MAZE THERAPEUTICS INC
$150M5.0M3.3%09
PHAT
PHATHOM PHARMACEUTICALS INC
$135M12.5M2.9%10
PVLA
PALVELLA THERAPEUTICS INC NE
$135M882K2.9%

Filing history

2026Q2Jun 30
$4.6B▲ 18.2%
41 positionsView →2026Q1Mar 31
$3.9B▲ 4.4%
38 positionsView →2025Q4Dec 31
$3.7B▲ 93.0%
40 positionsView →2025Q3Sep 30
$1.9B▼ 22.9%
33 positionsView →2025Q2Jun 30
$2.5B▲ 108.0%
49 positionsLocked2025Q1Mar 31
$1.2B▼ 50.1%
32 positionsLocked2024Q4Dec 31
$2.4B▼ 3.4%
50 positionsLocked2024Q3Sep 30
$2.5B▲ 16.7%
53 positionsLocked2024Q2Jun 30
$2.1B▼ 9.8%
49 positionsLocked2024Q1Mar 31
$2.4B▲ 26.7%
50 positionsLocked2023Q4Dec 31
$1.9B▲ 24.2%
49 positionsLocked2023Q3Sep 30
$1.5B▼ 10.1%
52 positionsLocked
Showing 12 of 18